Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Both colorectal (CRC, 15%) and endometrial cancers (EC, 30%) exhibit microsatellite instability (MSI) due to MLH1 hypermethylation and silencing. The MLH1 promoter polymorphism, rs1800734 is associated with MSI CRC risk, increased methylation and reduced MLH1 expression. In EC samples, we investigated rs1800734 risk using MSI and MSS cases and controls. We found no evidence that rs1800734 or other MLH1 SNPs were associated with the risk of MSI EC. We found the rs1800734 risk allele had no effect on MLH1 methylation or expression in ECs. We propose that MLH1 hypermethylation occurs by different mechanisms in CRC and EC.

Original publication

DOI

10.1186/s13148-020-00889-3

Type

Journal article

Journal

Clinical epigenetics

Publication Date

07/2020

Volume

12

Addresses

Cancer Gene Regulation Group, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.

Keywords

Humans, Endometrial Neoplasms, RNA, Messenger, Risk Assessment, DNA Methylation, Gene Silencing, Polymorphism, Single Nucleotide, Alleles, Female, Microsatellite Instability, Meta-Analysis as Topic, Promoter Regions, Genetic, Epigenomics, MutL Protein Homolog 1